{"filings":[{"id":92163,"accession_number":"0001193125-26-160421","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Lyra Therapeutics terminates Waltham sublease; pays $2.1M termination fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Termination of sublease for 23,704 sq ft at 880 Winter Street, Waltham, MA, effective March 31, 2026.","Company pays $2,100,000 termination payment; rent obligations ceased January 31, 2026.","Upon surrender and payment, RVAC Medicines will release $600,501 letter of credit security deposit.","Sublease originally dated December 21, 2023; premises must be surrendered by May 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92162,"accession_number":"0001193125-26-150441","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Lyra Therapeutics terminates two leases, forfeits $1.4M deposits and pays $2.5M in fees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Watertown lease (22,343 SF): forfeits $302,514.84 LC deposit + pays $1M modification; lease ends May 31, 2026.","Waltham lease (28,858 SF): forfeits $1,089,389 LC deposit + pays $1.5M termination fee; lease ends May 31, 2026.","Contingent: if Sale Transaction closes, Lyra pays 10% of Net Cash up to $1.5M.","Rent obligations ceased Jan 31, 2026 (Watertown) and Mar 31, 2026 (Waltham)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102791,"accession_number":"0001193125-26-108439","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lyra Therapeutics to suspend trading on Nasdaq March 17 after delisting appeal withdrawal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company withdrew appeal of February 2, 2026 Nasdaq delisting determination.","Nasdaq confirmed suspension of common stock trading at open on March 17, 2026.","Nasdaq will file Form 25 with SEC after internal procedural periods elapse.","No trading halt or additional compliance period cited; delisting is final."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102790,"accession_number":"0001193125-26-083251","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["2.04"],"status":"ready","headline":"Lyra Therapeutics receives default notice for $484K unpaid rent; wind-down continues","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received default notice from sublessor RVAC on Feb 23, 2026 for unpaid rent at Waltham office.","Aggregate unpaid rent totals $484,431.92 as of the notice date.","Company previously announced ceasing operations and wind-down on Jan 12, 2026.","Proposed sublease termination with Jan 31, 2026 surrender, but parties could not agree.","No assurance that obligations can be resolved outside of a bankruptcy process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102789,"accession_number":"0001193125-26-041191","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq notifies Lyra Therapeutics of delisting; company deemed a public shell","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq cites public shell status after suspension of lead drug LYR-210 and near-complete workforce reduction.","Nasdaq also cites non-compliance with minimum $2.5M equity listing rule.","Company has requested hearing to appeal delisting; stay in effect pending panel decision.","CEO and CFO now consultants; no ongoing operations after workforce reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102788,"accession_number":"0001193125-26-009772","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.05","5.02","8.01"],"status":"ready","headline":"Lyra suspends LYR-210 development, lays off nearly all staff; CEO/CFO become consultants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved plan to suspend LYR-210 development and reduce workforce affecting substantially all employees, effective Jan 12, 2026.","CEO Dr. Maria Palasis and CFO Jason Cavalier terminated; they signed consulting agreements with monthly fees of $78,125 and $55,555.50, respectively.","Cash and equivalents $22.1M as of Sep 30, 2025; expected runway extended to Q3 2026.","Engaged SSG Capital Advisors to explore strategic alternatives; no assurance of any transaction.","Positive ENLIGHTEN 2 Phase 3 data for LYR-210 (June 2025) but capital constraints force halt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119022,"accession_number":"0001193125-25-277515","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lyra Therapeutics reports Q3 net loss $6.0M, plans new Phase 3 trial for LYR-210","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $22.1M at Sep 30, 2025; cash runway into Q3 2026.","Net loss for Q3 2025 was $6.0M, down from $11.9M in Q3 2024.","R&D expenses decreased 32% to $4.0M; G&A decreased 43% to $2.2M due to cost reductions.","Planning confirmatory Phase 3 trial of LYR-210 for CRS without nasal polyps following FDA meeting.","Presented positive ENLIGHTEN 2 Phase 3 results at AAO-HNS meeting in October 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-14.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":391000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135567,"accession_number":"0001193125-25-195384","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lyra Therapeutics posts corporate presentation; content not detailed in filing extract","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation posted on Sept 4, 2025, on Lyra Therapeutics website.","Company ticker: LYRA (NASDAQ). No other specific updates provided in this filing.","Presentation may be used in investor discussions; details not available from form text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135566,"accession_number":"0001193125-25-186437","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lyra Therapeutics receives Nasdaq deficiency notice for equity below $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity as of June 30, 2025 was ~$1.6M, below the $2.5M continued listing requirement.","Company has 45 calendar days (until October 4, 2025) to submit a plan to regain compliance to Nasdaq.","If plan is accepted, Nasdaq may grant up to 180 additional calendar days to evidence compliance.","Failure to regain compliance could lead to delisting; Company may appeal to a Nasdaq Hearings Panel.","No immediate effect on listing or trading of common stock under symbol LYRA on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135565,"accession_number":"0000950170-25-107339","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lyra Therapeutics Q2 2025 net loss $7.4M; cash $29.8M; ENLIGHTEN 2 Phase 3 met primary endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q2 2025 $7.4M vs $48.1M YoY due to lower R&D and no impairment charges.","Cash $29.8M at June 30, 2025; $5.0M gross financing extends runway into Q3 2026.","ENLIGHTEN 2 Phase 3 met primary endpoint: 3CS improvement -1.13 (p=0.0078) at week 24; key secondary endpoints also met.","Preparing for Type C meeting with FDA in H2 2025 to align on NDA submission path for LYR-210 in CRS without nasal polyps.","Completed 1-for-50 reverse stock split in May; regained Nasdaq minimum bid compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":366000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135564,"accession_number":"0001193125-25-171647","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Executive Chairman Harlan Waksal departs Lyra; CEO Palasis becomes Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Harlan W. Waksal's employment terminated effective August 1, 2025; he resigned from Board.","Dr. Waksal eligible for severance per employment agreement upon signing separation and release.","Maria Palasis, President & CEO, appointed Chair of the Board effective immediately.","Jim Tobin remains as Lead Independent Director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152563,"accession_number":"0001193125-25-150301","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Lyra Therapeutics raises $5M upfront (up to $15M with warrant exercise) in equity offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront gross proceeds of $5.0M from sale of 423,372 shares (or pre-funded warrants) at $11.81 per share+private warrant.","Additional up to $9.8M if private warrants (846,744 shares at $11.56) exercised fully; warrants expire 24 months after resale registration effective.","Net proceeds ~$4.3M after placement agent fees (7% cash fee plus 6.5% on future warrant exercises).","Proceeds to be used for working capital and potential clinical development/manufacturing of LYR-210 for chronic rhinosinusitis.","Company previously terminated ~87 employees after failed ENLIGHTEN 1 Phase 3 trial and faces going concern risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152562,"accession_number":"0001193125-25-144151","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lyra regains Nasdaq minimum bid price compliance after 12-day streak above $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice from Nasdaq on June 13, 2025, confirming compliance with Listing Rule 5550(a)(2).","Common stock maintained minimum bid price of $1.00 for 12 consecutive business days (May 28 - June 12, 2025).","The matter is now closed; no further action required from Nasdaq on this issue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152561,"accession_number":"0001193125-25-137418","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lyra posts corporate presentation; no financial results disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing indicates presentation posted to website for investor discussions.","No specific financial or operational updates contained in the 8-K.","Presentation likely contains pipeline and strategy overview; details not provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152560,"accession_number":"0001193125-25-132774","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.03","7.01","8.01","9.01"],"status":"ready","headline":"Lyra Therapeutics reports positive ENLIGHTEN 2 Phase 3 trial: LYR-210 meets primary endpoint in CRS (p=0.0078)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ENLIGHTEN 2 met primary endpoint: LYR-210 improved 3CS composite score vs sham at 24 weeks (-1.13, p=0.0078) in non-polyp patients.","Key secondary endpoints met in full population: 3CS (p=0.0209) and SNOT-22 (-8.7, p=0.0101) at 24 weeks; SNOT-22 improvement seen from week 4.","LYR-210 well-tolerated with safety similar to sham; pooled analysis in 64 nasal polyp patients showed positive trends in multiple endpoints.","Company plans to align with FDA on NDA submission in non-polyp patients and continue development in nasal polyp patients.","Effective May 27, 2025, company effected a 1-for-50 reverse stock split (ticker unchanged LYRA)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152559,"accession_number":"0001193125-25-122485","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Lyra Therapeutics approves 1-for-50 reverse stock split, effective May 27","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse-split authority at 1-for-10 to 1-for-50 range; Board set final ratio at 1-for-50.","Reverse split effective 5:00 p.m. ET May 27, 2025; split-adjusted trading starts May 28 under symbol LYRA.","No fractional shares issued; holders receive cash payment based on May 27 closing price.","CUSIP changes to 55234L204 after split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152558,"accession_number":"0000950170-25-064475","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lyra Therapeutics reports Q1 net loss of $8.5M; ENLIGHTEN 2 top-line results expected Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.5M ($0.13 per share) vs. $22.5M ($0.35) in Q1 2024; cash burn reduced YoY.","Cash & equivalents $31.7M at March 31, 2025, down from $40.6M at Dec 31, 2024.","Topline Phase 3 ENLIGHTEN 2 data for LYR-210 in CRS expected in Q2 2025; ~65 polyp patients across both ENLIGHTEN trials.","Plans a reverse stock split to comply with Nasdaq $1.00 minimum bid; stockholder vote on May 14, 2025.","R&D expenses fell to $4.9M from $18.2M YoY, driven by completion of BEACON and ENLIGHTEN 1 trials and May 2024 workforce reduction."],"consensus_eps_estimate":-6.9702,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":183000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171380,"accession_number":"0000950170-25-038742","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lyra Therapeutics reports FY2024 net loss $93.4M; ENLIGHTEN 2 top-line data expected Q2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss for FY2024 was $93.4M ($1.43 diluted EPS) vs $62.7M in FY2023; cash $40.6M as of Dec 31, 2024.","Top-line results from ENLIGHTEN 2 Phase 3 trial of LYR-210 in CRS expected in Q2 2025.","Positive post-hoc data from ENLIGHTEN 1 extension in polyp cohort; FDA alignment on registration path for CRSwNP.","Planned reverse stock split to maintain Nasdaq listing; requires shareholder approval in Q2 2025.","R&D expenses decreased to $43.8M from $48.0M due to trial completions and workforce reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171379,"accession_number":"0001193125-25-004428","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lyra Therapeutics posts corporate presentation; no new facts extractable from exhibit content provided","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished a corporate presentation as Exhibit 99.1 to the SEC on January 10, 2025.","The full content of the presentation is not included in the filing text submitted for analysis.","Investors should view the presentation on Lyra's website for any updates on strategy or pipeline.","No specific financial or operational numbers, guidance changes, or milestones are disclosed in the 8-K body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188363,"accession_number":"0001193125-24-278688","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lyra Therapeutics board members Altman and Poukalov resign; board rebalanced","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Altman and Konstantin Poukalov resigned from Lyra Therapeutics Board effective December 12, 2024.","Maria Palasis, Ph.D. moved from Class III to Class I director to rebalance board classes; term extended to 2027.","Board now consists of two Class I, two Class II, and two Class III directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188362,"accession_number":"0000950170-24-125455","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lyra Therapeutics Q3 net loss $11.9M; ENLIGHTEN 2 topline due Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash & equivalents $51.6M as of Sep 30, 2024; runway into Q1 2026.","R&D expenses fell to $5.9M from $12.4M YoY; G&A down to $3.9M from $5.0M.","ENLIGHTEN 2 pivotal trial fully enrolled Oct 2024; topline results expected Q2 2025.","ENLIGHTEN 1 extension study showed no product-related serious adverse events.","Net loss improved to $11.9M vs $15.7M in Q3 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":1325000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204840,"accession_number":"0000950170-24-097007","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lyra Therapeutics Q2 net loss $48.1M; workforce cut 75%; ENLIGHTEN 1 subgroup positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $48.1M vs $15.6M YoY, including $22.8M right-of-use asset impairment and $6.5M restructuring charge.","Cash $67.5M at June 30; expects runway into Q1 2026.","Further analysis of ENLIGHTEN 1 shows LYR-210 improved 3CS score by 2.25 points (p=0.0058) vs sham in CRS with nasal polyps.","Reduced workforce by ~75% (87 employees), halted manufacturing, paused LYR-220, and seeking subleases.","ENLIGHTEN 1 extension results expected Q4 2024; ENLIGHTEN 2 topline results expected 1H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":1130000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204839,"accession_number":"0001193125-24-182860","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lyra Therapeutics receives Nasdaq minimum bid price deficiency notice; has until Jan 15, 2025 to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Lyra on July 19, 2024 that its common stock (LYRA) closed below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until January 15, 2025, to regain compliance by closing at or above $1.00 for 10 consecutive days.","If not cured, Lyra may transfer to Nasdaq Capital Market and get an additional 180-day compliance period.","Failure to regain compliance could result in delisting; the company intends to monitor and consider available options.","Stock continues trading on Nasdaq Global Market under symbol LYRA during the cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221697,"accession_number":"0001193125-24-163395","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Lyra stockholders approve officer exculpation amendment and elect two Class I directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Officer exculpation amendment approved: 38.8M for, 1.2M against, 8k abstain.","Class I directors elected: Poukalov (38.6M for) and Snyderman (33.4M for).","BDO USA ratified as auditor for FY2024: 47.5M for, 47.7k against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221693,"accession_number":"0001193125-24-157373","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K/A","filed_at":"2024-06-07T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Lyra Therapeutics estimates $3.9-4.1M in charges from workforce reduction of up to 87 employees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved workforce reduction of up to 87 employees, effective May 21 and June 20, 2024.","Cost estimate: $3.9 to $4.1 million, primarily severance and benefits.","Majority of charges expected in Q2 2024.","Company previously could not estimate costs; this 8-K/A provides updated disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221696,"accession_number":"0001193125-24-143419","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["2.05","5.02"],"status":"ready","headline":"Lyra Therapeutics cuts workforce by up to 87 employees, CTO departing in restructuring","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved reduction of up to 87 employees, ~80 effective May 21 and ~7 effective June 20, 2024.","John E. Bishop (CTO) position eliminated; separation agreement to provide severance under employment agreement.","Retention payments approved: CEO Maria Palasis receives $375,000 and CFO Jason Cavalier receives $266,666, payable in three installments through May 1, 2025.","Company currently unable to estimate total costs associated with the workforce reduction; will file amendment later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221695,"accession_number":"0000950170-24-050525","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lyra Therapeutics Q1 net loss $22.5M; ENLIGHTEN 1 Phase 3 results expected in May 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $87.1M at March 31, 2024 vs $102.8M at Dec 31, 2023; cash runway into Q1 2025.","Net loss $22.5M vs $16.3M in Q1 2023; R&D expense $18.2M (up $5.6M YoY).","ENLIGHTEN 1 pivotal Phase 3 data for LYR-210 in CRS expected in May 2024.","ENLIGHTEN 2 enrollment completion expected H2 2024; LYR-220 end-of-Phase 2 meeting with FDA anticipated H2 2024.","BEACON Phase 2 data for LYR-220 to be presented at COSM on May 15, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":532000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221694,"accession_number":"0001193125-24-102914","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Edward T. Anderson resigns from Lyra board; Snyderman appointed to Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Edward T. Anderson resigned from Lyra's Board, Audit Committee, and Compensation Committee effective April 15, 2024.","Nancy L. Snyderman was appointed to the Audit Committee on April 15, 2024, filling the vacancy.","Anderson had been a Board member since 2019 and an investor since 2006; no reason for departure given."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241238,"accession_number":"0000950170-24-034701","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lyra Therapeutics reports FY2023 net loss $62.7M; ENLIGHTEN I Phase 3 topline expected Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $62.7M in FY2023 ($15.1M Q4); R&D $48.0M, G&A $19.1M; cash $102.8M, runway into Q1 2025.","Topline results from ENLIGHTEN I Phase 3 trial of LYR-210 in CRS anticipated Q2 2024.","ENLIGHTEN II enrollment completion expected H2 2024; ENLIGHTEN I 52-week extension results Q4 2024.","BEACON Phase 2 of LYR-220 met safety endpoint; significant SNOT-22 (−16.8; p=0.007) and 3CS (−1.50; p=0.02) improvement vs sham at week 24."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241237,"accession_number":"0000950170-24-023918","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lyra Therapeutics doubles Executive Chair salary to $400k retroactive to Jan 1, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved salary increase for Executive Chair Harlan Waksal from $200k to $400k annually.","Increase is retroactive to January 1, 2024.","No other compensation changes for officers were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241236,"accession_number":"0000950170-24-002661","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lyra reports BEACON Phase 2 smell-loss data: 0.87 improvement at week 24 (p=0.026)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BEACON Phase 2 trial: 0.87 improvement in smell loss vs control at week 24 (p=0.026) in patients with impaired smell at baseline.","Data filed in corporate presentation posted Jan 8, 2024; subset analysis shows statistically significant benefit.","No safety or additional efficacy details disclosed; further development plans not specified.","Lyra is a clinical-stage biotech focused on chronic rhinosinusitis therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258700,"accession_number":"0000950170-23-073432","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2023-12-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lyra Therapeutics subleases ~23,704 sq ft lab/office in Waltham, MA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sublease with RVAC Medicines for 23,704 sq ft at 880 Winter Street, Waltham, MA.","Term expected to start Jan 1, 2024; expires Nov 30, 2032.","Monthly base rent $150,125.33 (~$1.8M annual); 3% annual escalator; first two months rent-free.","Requires $450,375.99 letter of credit as security deposit; also pays share of operating expenses, utilities, taxes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258699,"accession_number":"0000950170-23-071093","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Lyra Therapeutics amends bylaws to align with universal proxy rules and update stockholder meeting procedures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amended bylaws effective Dec 14, 2023, addressing SEC universal proxy Rule 14a-19.","New rules require additional disclosures from stockholders nominating directors or proposing business.","Stockholders soliciting proxies must use a non-white proxy card; obsolete provisions deleted.","Changes are procedural and governance-related; no financial impact disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258698,"accession_number":"0000950170-23-060243","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lyra reports Q3 net loss $15.7M; Phase 2 CT data shows objective improvement in CRS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["CT data for LYR-220: ethmoid sinus opacification improved vs sham (p=0.035) at 24 weeks.","SNOT-22 improvement maintained at Week 28: -17.6 points (p=0.007) vs sham.","Cash, equivalents and investments $102.6M, sufficient into Q1 2025.","ENLIGHTEN I Phase 3 fully enrolled; topline results expected 1H 2024.","Net loss $15.7M vs $14.8M year-over-year; R&D spend up to $12.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":1412000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276010,"accession_number":"0001193125-23-233432","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2023-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lyra posts slide deck with BEACON Phase 2 topline results for LYR-220 in CRS","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["LYR-220 evaluated in Phase 2 BEACON study for chronic rhinosinusitis with/without polyps in patients with prior ethmoidectomy.","Topline results posted as slide deck on Lyra investor website on Sept 12, 2023; no specific data included in this 8-K text.","Study identifier NCT05035654 on clinicaltrials.gov; two-part, patient-blinded, randomized trial.","No financial impact or guidance changes announced; materiality depends on the actual results not seen here."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276009,"accession_number":"0001193125-23-227626","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lyra Therapeutics enters $50M at-the-market equity offering with Cantor Fitzgerald","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters Controlled Equity Offering Sales Agreement to sell up to $50.0M of common stock through Cantor Fitzgerald.","Shares sold in at-the-market offerings; Cantor receives 3.0% commission on gross proceeds.","Company has no obligation to sell any shares and may suspend or terminate offering at any time.","Offering registered under existing S-3 shelf; prospectus supplement filed September 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276008,"accession_number":"0000950170-23-039769","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lyra Therapeutics Q2 net loss $15.6M; cash $116.2M after $46.7M placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $116.2M at June 30, 2023, up from $82.7M at March 31, 2023.","Net loss $15.6M for Q2 2023 vs $14.4M in Q2 2022; R&D expense flat at $10.8M.","ENLIGHTEN I Phase 3 enrollment completion expected in weeks; data 1H 2024.","BEACON Phase 2 topline results for LYR-220 now expected September 2023.","Private placement closed May 31, 2023 yielded net proceeds of $46.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":868000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276007,"accession_number":"0000950170-23-032992","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2023-07-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lyra Therapeutics extends office lease through April 2027, modifies rent and abatements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease term extended from April 30, 2024 to April 30, 2027.","Base rent from May 1, 2024 set at $95.67/sq ft/year (~22,343 sq ft), with 3% annual increases.","Rent abatements for May 2024 and May 2025 (one month each).","Tenant's early termination right (Sixth Amendment Section 4) revoked.","Landlord responsible for building system repairs for 30 days after Extension Commencement Date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293640,"accession_number":"0000950170-23-028281","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lyra Therapeutics annual meeting results: all proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["19,500,381 shares present (≈60% of outstanding); quorum met.","Elected Class III directors Palasis (16.4M for), Smith (16.3M for), Tobin (16.6M for).","Ratified BDO USA as independent auditor for FY 2023 (9.5M for, 8K against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293639,"accession_number":"0001193125-23-157998","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2023-05-31T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Lyra Therapeutics announces $50M private placement; extends cash runway into Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$50M from sale of ~17.7M shares, ~2.4M pre-funded warrants, and ~10.0M purchase warrants at $2.4925 per unit.","Pre-funded warrants exercisable immediately at $0.001/share, expire May 2028; purchase warrants exercisable from Nov 2023 at $2.673/share, expire Nov 2028.","Cash, cash equivalents and short-term investments stood at $82.7M as of Q1 2023; combined with net proceeds expected to fund operations into Q1 2025.","Cantor Fitzgerald and William Blair acted as joint lead placement agents; H.C. Wainwright as co-placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293638,"accession_number":"0000950170-23-021491","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lyra Therapeutics Q1 2023 net loss $16.3M; ENLIGHTEN I Phase 3 on track for 1H 2024 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.3M for Q1 2023, compared to $11.9M in Q1 2022.","Cash, equivalents, and short-term investments $82.7M at March 31, 2023; cash runway into mid-Q2 2024.","ENLIGHTEN I Phase 3 trial (LYR-210, pre-surgical CRS) enrollment ongoing; data expected 1H 2024.","ENLIGHTEN II Phase 3 trial restarted enrollment in April 2023; completion expected H2 2024.","BEACON Phase 2 trial (LYR-220, post-surgical CRS) enrollment complete; data expected Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":410000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314273,"accession_number":"0000950170-23-010621","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Lyra Therapeutics reports FY2022 net loss $55.3M; cash $97.9M; ENLIGHTEN I on track for mid-2023 enrollment completion","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2022 $55.3M vs $43.5M in 2021; Q4 net loss $14.2M.","Cash and investments $97.9M as of Dec 31, 2022; sufficient into mid-2024.","ENLIGHTEN I Phase 3 enrollment completion on track for mid-2023; ENLIGHTEN II resume enrollment Q2 2023 (ahead of prior Q3 2023).","BEACON Phase 2 data for LYR-220 expected Q4 2023.","Transitioned manufacturing in-house to prepare for commercial production."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332695,"accession_number":"0000950170-22-025323","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2022-11-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lyra Therapeutics extends office lease through April 2024 at $93/sq ft","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Extended lease for 22,343 sq ft in Watertown, MA from Apr 2023 to Apr 2024.","Base rent increases to $93/sq ft/year starting May 1, 2023.","Tenant may terminate lease after Jan 1, 2024 with 60 days' notice.","Premises on as-is basis; no tenant improvement allowance provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332694,"accession_number":"0000950170-22-023254","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lyra Therapeutics Q3 net loss $14.8M; pauses ENLIGHTEN II enrollment for in-house mfg","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.8M for Q3 2022, compared to $11.1M in Q3 2021.","Cash and equivalents $109.6M; expected to fund operations through mid-2024.","ENLIGHTEN I Phase 3 trial on track for enrollment completion mid-2023; ENLIGHTEN II paused, resuming Q3 2023.","BEACON Phase 2 trial of LYR-220 advanced to randomized stage; initial data submitted for 2023 meeting.","R&D expenses rose to $10.0M from $7.1M year-over-year due to clinical trial costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":1352000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332693,"accession_number":"0000950170-22-020211","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2022-10-26T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Lyra Therapeutics restates Q1/Q2 2022 financials due to $5M milestone error","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee concludes Q1 and Q2 2022 financials no longer reliable due to $5.0M milestone revenue recognition error from LianBio agreement.","Restatement will correct the treatment of variable consideration; cash position unchanged.","Material weakness identified in internal controls over accounting for complex, nonrecurring transactions.","Company expects to file restated financials as soon as practicable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350154,"accession_number":"0001564590-22-031438","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2022-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lyra presents additional Phase 2 LANTERN data for LYR-210 at ARS meeting","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Posted slide presentation with additional Phase 2 results from LANTERN trial of LYR-210 for chronic rhinosinusitis.","Data presented at 68th Annual Meeting of the American Rhinologic Society on September 10, 2022.","Top-line results from LANTERN previously reported on April 11, 2021; this update includes further analysis.","Slide deck available on Lyra's investor website and attached as exhibit to the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350153,"accession_number":"0001564590-22-028601","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lyra Therapeutics Q2 net loss $14.5M; cash $120.7M; CMO appointed; Phase 3 enrollment ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.5M for Q2 2022 vs $11.0M in Q2 2021; R&D expenses $10.8M.","Cash and equivalents $120.7M as of June 30, 2022; cash runway to mid-2024.","Closed private placement of ~$96.3M net proceeds in April 2022.","Appointed Richard Nieman, MD as Chief Medical Officer.","ENLIGHTEN Phase 3 program enrolling; ENLIGHTEN II first patient expected Q3; enrollment complete mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":5774000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367288,"accession_number":"0001564590-22-023497","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lyra Therapeutics stockholders elect three Class II directors and ratify auditor at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Michael Altman, C. Ann Merrifield, and Harlan Waksal elected as Class II directors with votes for 19.7M-19.8M each; 2.5M broker non-votes.","Ratification of BDO USA as independent auditor for FY2022: 22.3M for, 25.5K against, 16.5K abstained.","Approximately 70.19% of outstanding shares (22.3M of ~31.8M) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367287,"accession_number":"0001193125-22-163916","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2022-05-31T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Lyra Therapeutics enters 10-year lease for 28,858 sq ft office/lab in Waltham, MA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease with BXP Waltham Woods for 28,858 sq ft at 880 Winter Street, Waltham, MA.","Term 10 years plus 5-year extension option; base rent starts at $181,565/month, 3% annual increase.","Landlord provides up to $5,915,890 in tenant improvements; security deposit letter of credit $1,089,389.","Commencement expected on or before May 1, 2023; rent begins 60 days after delivery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367286,"accession_number":"0001564590-22-019094","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lyra Therapeutics Q1 2022 net loss of $7.0M; secures $100.5M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q1 2022 was $7.0M, compared to $7.8M in Q1 2021.","Cash and cash equivalents at March 31, 2022 were $33.8M; subsequently received $100.5M gross proceeds from April private placement.","Research and development expenses increased to $8.5M from $4.8M, driven by clinical trial costs.","ENLIGHTEN Phase 3 program for LYR-210 enrollment ongoing; ENLIGHTEN II initiation targeted mid-2022.","BEACON Phase 2 trial for LYR-220 first patient treated in Australia; Part 2 expected in U.S. in Q2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":5367000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1284274.4793128204,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-10T23:59:59+00:00|367286"}